Comparison of human ocular distribution of bimatoprost and latanoprost

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 2, 2012, Pages 134-145

  Ichhpujani, Parul ^a   Katz, L Jay ^a   Hollo, Gabor ^b   Shields, Carol L ^a   Shields, Jerry A ^a   Marr, Brian ^a   Eagle, Ralph ^a   Alvim, Heryberto ^a   Wizov, Sheryl S ^a   Acheampong, Andrew ^c   Chen, June ^c   Wheeler, Larry A ^c  

^a Willis Eye Institute   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; PRODRUG;

AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CILIARY BODY; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; ENUCLEATION; HUMAN; HUMAN TISSUE; HYDROLYSIS; IN VIVO STUDY; INTRAOCULAR PRESSURE; INTRAOCULAR TUMOR; IRIS; LIQUID CHROMATOGRAPHY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCLERA; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TARGET ORGAN;

AMIDES; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOPROSTENOL; DRUG ADMINISTRATION SCHEDULE; EYE; EYE ENUCLEATION; HUMANS; LIMIT OF DETECTION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TANDEM MASS SPECTROMETRY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84859381344     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0097     Document Type: Article

References (29)

1. Frenkel, R.E., Noecker, R.J., and Craven, E.R. Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%. Curr. Med. Res. Opin. 24:919-923, 2008. (Pubitemid 351579150)
2. Brubaker, R.F. Mechanism of action of bimatoprost (Lumi-gan). Surv. Ophthalmol. 45(Suppl 4):S347-S351, 2001.
3. 2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111:1351-1358, 1993. (Pubitemid 23296779)
4. Christiansen, G.A., Nau, C.B., McLaren, J.W., and Johnson, D.H. Mechanism of ocular hypotensive action of bimato-prost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 111:1658-1662, 2004. (Pubitemid 39179679)
5. Lim, K.S., Nau, C.B., O'Byrne, M.M., et al. Mechanism ofaction of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008;115:790-795.e4.
6. Sjöquist, B., and Stjernschantz, J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthal-mol. 47(Suppl 1):S6-S12, 2002. (Pubitemid 35232215)
7. Calissendorff, B., Sjöquist, B., Högberg, G., and Grunge-Lowerud, A. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther. 18:127-131, 2002. (Pubitemid 34297296)
8. Camras, C.B., Toris, C.B., Sjoquist, B., et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology 111:2193-2198, 2004. (Pubitemid 39575588)
9. Cantor, L.B., Hoop, J., Wudunn, D., et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br. J. Ophthalmol. 91:629-632, 2007. (Pubitemid 46716532)
10. Faulkner, R., Sharif, N.A., Orr, S., et al. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRA-VATAN. J. Ocul. Pharmacol. Ther. 26:147-156, 2010.
11. Chien, D.S., Homsy, J.J., Gluchowski, C., and Tang-Liu, D.D. Corneal and conjunctival/sclera penetration of p-aminoclo-nidine, AGN 190342, and clonidine in rabbit eyes. Curr. Eye Res. 9:1051-1059, 1990.
12. Schoenwald, R.D., Deshpande, G.S., Rethwisch, D.G., and Barfknecht, C.F. Penetration into the anterior chamber via the conjunctival/sclera pathway. J. Ocul. Pharmacol. Ther. 13:41-59, 1997. (Pubitemid 27130721)
13. Lawrence, M.S., and Miller, J.W. Ocular tissue permeabilities. Int. Ophthalmol. Clin. 44:53-61, 2004. (Pubitemid 38955661)
14. Bhal, S.K., Kassam, K., Peirson, I.G., and Pearl, G.M. The rule of five revisited: Applying Log D in place of Log P in drug-likeness filters. Mol. Pharm. 4:556-560, 2007. (Pubitemid 47310166)
15. 2a-1-isopropyl ester. Exp. Eye Res. 44:217-226, 1987. (Pubitemid 17060567)
16. Bean, G.W., and Camras, C.B. Commercially available prosta-glandin analogs for the reduction of intraocular pressure: Similarities and differences. Surv. Ophthalmol. 53(Suppl 1):S69-S84, 2008.
17. Woodward, D.F., Krauss, A.H., Chen, J., et al. The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. 45(Suppl 4):S337-S345, 2001.
18. Woodward, D.F., Phelps, R.L., Krauss, A.H., et al. Bimato-prost: A novel antiglaucoma agent. Cardiovasc. Drug Rev. 22:103-120, 2004.
19. Woodward, D.F., Krauss, A.H., Chen, J.,etal. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305:772-785, 2003. (Pubitemid 36459199)
20. Chen, J., Senior, J., Marshall, K., et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br. J. Pharmacol. 144:493-501, 2005. (Pubitemid 40349456)
21. Chen, J., Lu, R.T., Lai, R., et al. Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr. Eye Res. 34:184-195, 2009.
22. Stamer, W.D., Piwnica, D., Jolas, T., et al. Cellular basis for bimatoprost effects on human conventional outflow. Invest. Ophthalmol. Vis. Sci. 51:5176-5181, 2010.
23. Liang, Y., Woodward, D.F., Guzman, V.M., et al. Identification and pharmacological characterization of the prosta-glandin FP receptor and FP receptor variant complexes. Br. J. Pharmacol. 154:1079-1093, 2008. (Pubitemid 351915050)
24. Jones, R.L., Giembycz, M.A., and Woodward, D.F. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br. J. Pharmacol. 158(1):104-145, 2009.
25. Davies, S.S., Ju, W.K., Neufeld, A.H., Abran, D., Chemtob, S., and Roberts, L.J. 2nd. Hydrolysis of bimatoprost (Lumi-gan) to its free acid by ocular tissue in vitro. J. Ocul. Pharmacol. Ther. 19:45-54, 2003. (Pubitemid 36249879)
26. 2a by human and rabbit ocular tissue. J. Ocul. Pharmacol. Ther. 19:97-103, 2003. (Pubitemid 36539135)
27. Holmstrom, S., Buchholz, P., Walt, J., Wickstrøm, J., and Aagren, M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr. Med. Res. Opin. 21:1875-1883, 2005. (Pubitemid 41667256)
28. Sharif, N.A., and Klimko, P. Update and commentary on the pro-drug bimatoprost and a putative 'prostamide receptor'. Expert Rev. Ophthalmol. 4:477-489, 2009.
29. 2a indicates different structural determinants for binding to the prostaglandin F receptor versus the prostaglandin transporter. Mol. Pharmacol.